Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells 2,519 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 2,519 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $4.86, for a total transaction of $12,242.34. Following the sale, the chief technology officer owned 205,430 shares in the company, valued at approximately $998,389.80. This trade represents a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $5,016.10.

SOPHiA GENETICS Stock Down 0.3%

SOPHiA GENETICS stock traded down $0.01 during mid-day trading on Wednesday, reaching $4.89. 64,929 shares of the company’s stock were exchanged, compared to its average volume of 188,371. The company has a market cap of $334.64 million, a P/E ratio of -9.58 and a beta of 1.04. SOPHiA GENETICS SA has a twelve month low of $2.58 and a twelve month high of $5.70. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The company has a fifty day moving average of $4.78 and a 200-day moving average of $4.68.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Sell-side analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

SOPH has been the subject of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim lifted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Alta Wealth Advisors LLC purchased a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $6,708,000. Dimensional Fund Advisors LP lifted its position in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the last quarter. Polen Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $102,000. XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $55,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.